KRASis the most commonly mutated RAS family gene and is a primary cause of the occurrence of several types of cancer. However,KRASmutations have several unique and diverse molecular identities, making it difficult to find specific treatments. Here, we developed universal pegRNAs which can correct all types of G12 and G13 oncogenicKRASmutations with CRISPR-mediated prime editors (PEs). The universal pegRNA successfully corrected 12 types ofKRASmutations, accounting for 94% of all knownKRASmutations, by up to 54.8% correction frequency in HEK293T/17 cells. We also applied the universal pegRNA to correct endogenousKRASmutations in human cancer cells and found that G13DKRASmutation was successfully corrected to wild-typeKRASsequences with up to 40.6% correction frequency without indel mutations. We propose prime editing with the universal pegRNA as a ‘one–to–many’ potential therapeutic strategy forKRASoncogene variants.